Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
CNS Drugs
Erschienen in: CNS Drugs 3/2017

01.03.2017 | Leading Article

Nogo-A Antibodies for Progressive Multiple Sclerosis

verfasst von: Benjamin V. Ineichen, Patricia S. Plattner, Nicolas Good, Roland Martin, Michael Linnebank, Martin E. Schwab

Erschienen in: CNS Drugs | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

Most of the current therapies, as well as many of the clinical trials, for multiple sclerosis (MS) target the inflammatory autoimmune processes, but less than 20% of all clinical trials investigate potential therapies for the chronic progressive disease stage of MS. The latter is responsible for the steadily increasing disability in many patients, and there is an urgent need for novel therapies that protect nervous system tissue and enhance axonal growth and/or remyelination. As outlined in this review, solid pre-clinical data suggest neutralization of the neurite outgrowth inhibitor Nogo-A as a potential new way to achieve both axonal and myelin repair. Several phase I clinical studies with anti-Nogo-A antibodies have been conducted in different disease paradigms including MS and spinal cord injury. Data from spinal cord injury and amyotrophic lateral sclerosis (ALS) trials accredit a good safety profile of high doses of anti-Nogo-A antibodies administered intravenously or intrathecally. An antibody against a Nogo receptor subunit, leucine rich repeat and immunoglobulin-like domain-containing protein 1 (LINGO-1), was recently shown to improve outcome in patients with acute optic neuritis in a phase II study. Nogo-A-suppressing antibodies could be novel drug candidates for the relapsing as well as the progressive MS disease stage. In this review, we summarize the available pre-clinical and clinical evidence on Nogo-A and elucidate the potential of Nogo-A-antibodies as a therapy for progressive MS.
Literatur
1.
World Health Organization. Multiple Sclerosis International Federation. Atlas: Multiple Sclerosis Resources in the World 2008. Geneva: World Health Organization; 2008. p. 13–7.
2.
Trapp BD, Nave KA. Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci. 2008;31:247–69.PubMedCrossRef
3.
Sawcer S, Hellenthal G, Pirinen M, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 2011;476(7359):214–9.PubMedPubMedCentralCrossRef
4.
Tallantyre EC, Bo L, Al-Rawashdeh O, et al. Greater loss of axons in primary progressive multiple sclerosis plaques compared to secondary progressive disease. Brain. 2009;132(Pt 5):1190–9.PubMedCrossRef
5.
Fox RJ, Thompson A, Baker D, et al. Setting a research agenda for progressive multiple sclerosis: the International Collaborative on Progressive MS. Mult Scler (Houndmills, Basingstoke, England). 2012;18(11):1534–40.CrossRef
6.
Torkildsen O, Myhr KM, Bo L. Disease-modifying treatments for multiple sclerosis: a review of approved medications. Eur J Neurol. 2016;23(Suppl. 1):18–27.PubMedCrossRef
7.
Coles AJ, Cox A, Le Page E, et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol. 2006;253(1):98–108.PubMedCrossRef
8.
Hauser SL, Chan JR, Oksenberg JR. Multiple sclerosis: prospects and promise. Ann Neurol. 2013;74(3):317–27.PubMedCrossRef
9.
Kappos L, Polman C, Pozzilli C, et al. Final analysis of the European multicenter trial on IFNbeta-1b in secondary-progressive MS. Neurology. 2001;57(11):1969–75.PubMedCrossRef
10.
Hartung HP, Gonsette R, Konig N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet. 2002;360(9350):2018–25.PubMedCrossRef
11.
Kappos L, Wiendl H, Selmaj K, et al. Daclizumab HYP versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2015;373(15):1418–28.PubMedCrossRef
12.
Gold R, Giovannoni G, Selmaj K, et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet. 2013;381(9884):2167–75.PubMedCrossRef
13.
Montalban X, Hemmer B, Rammohan K, et al. Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis: results of the phase III double-blind, placebo-controlled ORATORIO study (S49.001). Neurology. 2016;86(16 Suppl.):S49-001.
14.
Hauser S, Comi G, Hartung H-P, et al. Efficacy and safety of ocrelizumab in relapsing multiple sclerosis-results of the interferon-beta-1a-controlled, double-blind, phase III OPERA I and II studies. Mult Scler. 2015;61–2.
15.
McGinley MP, Moss BP, Cohen JA. Safety of monoclonal antibodies for the treatment of multiple sclerosis. Exp Opin Drug Saf. 2017;16(1):89–100.CrossRef
16.
Ontaneda D, Fox RJ, Chataway J. Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives. Lancet Neurol. 2015;14(2):208–23.PubMedPubMedCentralCrossRef
17.
18.
19.
Shirani A, Okuda DT, Stuve O. Therapeutic advances and future prospects in progressive forms of multiple sclerosis. Neurotherapeutics. 2016;13(1):58–69.PubMedPubMedCentralCrossRef
20.
Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med. 1998;338(5):278–85.PubMedCrossRef
21.
Stadelmann C. Multiple sclerosis as a neurodegenerative disease: pathology, mechanisms and therapeutic implications. Curr Opin Neurol. 2011;24(3):224–9.PubMedCrossRef
22.
Weinshenker BG. The natural history of multiple sclerosis: update 1998. Semin Neurol. 1998;18(3):301–7.PubMedCrossRef
23.
Filippi M, Rocca MA, De Stefano N, et al. Magnetic resonance techniques in multiple sclerosis: the present and the future. Arch Neurol. 2011;68(12):1514–20.PubMedCrossRef
24.
Criste G, Trapp B, Dutta R. Axonal loss in multiple sclerosis: causes and mechanisms. Handb Clin Neurol. 2014;122:101–13.PubMedCrossRef
25.
Mahad DH, Trapp BD, Lassmann H. Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol. 2015;14(2):183–93.PubMedCrossRef
26.
Fischer MT, Sharma R, Lim JL, et al. NADPH oxidase expression in active multiple sclerosis lesions in relation to oxidative tissue damage and mitochondrial injury. Brain. 2012;135(Pt 3):886–99.PubMedPubMedCentralCrossRef
27.
Campbell GR, Kraytsberg Y, Krishnan KJ, et al. Clonally expanded mitochondrial DNA deletions within the choroid plexus in multiple sclerosis. Acta Neuropathol. 2012;124(2):209–20.PubMedPubMedCentralCrossRef
28.
Witte ME, Mahad DJ, Lassmann H, van Horssen J. Mitochondrial dysfunction contributes to neurodegeneration in multiple sclerosis. Trends Mol Med. 2014;20(3):179–87.PubMedCrossRef
29.
Dendrou CA, Fugger L, Friese MA. Immunopathology of multiple sclerosis. Nat Rev Immunol. 2015;15(9):545–58.PubMedCrossRef
30.
Sorbara CD, Wagner NE, Ladwig A, et al. Pervasive axonal transport deficits in multiple sclerosis models. Neuron. 2014;84(6):1183–90.PubMedCrossRef
31.
Davies AL, Desai RA, Bloomfield PS, et al. Neurological deficits caused by tissue hypoxia in neuroinflammatory disease. Ann Neurol. 2013;74(6):815–25.PubMedCrossRef
32.
Desai RA, Davies AL, Tachrount M, et al. Cause and prevention of demyelination in a model multiple sclerosis lesion. Ann Neurol. 2016;79(4):591–604.PubMedPubMedCentralCrossRef
33.
Lassmann H. Demyelination and neurodegeneration in multiple sclerosis: the role of hypoxia. Ann Neurol. 2016;79(4):520–1.PubMedCrossRef
34.
Patani R, Balaratnam M, Vora A, Reynolds R. Remyelination can be extensive in multiple sclerosis despite a long disease course. Neuropathol Appl Neurobiol. 2007;33(3):277–87.PubMedCrossRef
35.
Franklin RJ, Gallo V. The translational biology of remyelination: past, present, and future. Glia. 2014;62(11):1905–15.PubMedCrossRef
36.
Nave KA. Myelination and support of axonal integrity by glia. Nature. 2010;468(7321):244–52.PubMedCrossRef
37.
Franklin RJ, Ffrench-Constant C, Edgar JM, Smith KJ. Neuroprotection and repair in multiple sclerosis. Nat Rev Neurol. 2012;8(11):624–34.PubMedCrossRef
38.
Craner MJ, Newcombe J, Black JA, et al. Molecular changes in neurons in multiple sclerosis: altered axonal expression of Nav1.2 and Nav1.6 sodium channels and Na+/Ca2+ exchanger. Proc Natl Acad Sci USA. 2004;101(21):8168–73.PubMedPubMedCentralCrossRef
39.
Vergo S, Craner MJ, Etzensperger R, et al. Acid-sensing ion channel 1 is involved in both axonal injury and demyelination in multiple sclerosis and its animal model. Brain. 2011;134(Pt 2):571–84.PubMedCrossRef
40.
Friese MA, Craner MJ, Etzensperger R, et al. Acid-sensing ion channel-1 contributes to axonal degeneration in autoimmune inflammation of the central nervous system. Nat Med. 2007;13(12):1483–9.PubMedCrossRef
41.
Schattling B, Steinbach K, Thies E, et al. TRPM4 cation channel mediates axonal and neuronal degeneration in experimental autoimmune encephalomyelitis and multiple sclerosis. Nat Med. 2012;18(12):1805–11.PubMedCrossRef
42.
Friese MA, Schattling B, Fugger L. Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis. Nat Rev Neurol. 2014;10(4):225–38.PubMedCrossRef
43.
Frischer JM, Weigand SD, Guo Y, et al. Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque. Ann Neurol. 2015;78(5):710–21.PubMedPubMedCentralCrossRef
44.
Mews I, Bergmann M, Bunkowski S, et al. Oligodendrocyte and axon pathology in clinically silent multiple sclerosis lesions. Mult Scler. 1998;4(2):55–62.PubMedCrossRef
45.
Bjartmar C, Kidd G, Mork S, et al. Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients. Ann Neurol. 2000;48(6):893–901.PubMedCrossRef
46.
Sospedra M, Martin R. Immunology of multiple sclerosis. Ann Rev Immunol. 2005;23:683–747.CrossRef
47.
Dubois-Dalcq M, Ffrench-Constant C, Franklin RJ. Enhancing central nervous system remyelination in multiple sclerosis. Neuron. 2005;48(1):9–12.PubMedCrossRef
48.
Wootla B, Denic A, Watzlawik JO, et al. Antibody-mediated oligodendrocyte remyelination promotes axon health in progressive demyelinating disease. Mol Neurobiol. 2016;53(8):5217–28.PubMedCrossRef
49.
Schwab ME. Functions of Nogo proteins and their receptors in the nervous system. Nat Rev Neurosci. 2010;11(12):799–811.PubMedCrossRef
50.
Caroni P, Schwab ME. Antibody against myelin-associated inhibitor of neurite growth neutralizes nonpermissive substrate properties of CNS white matter. Neuron. 1988;1(1):85–96.PubMedCrossRef
51.
GrandPre T, Nakamura F, Vartanian T, Strittmatter SM. Identification of the Nogo inhibitor of axon regeneration as a reticulon protein. Nature. 2000;403(6768):439–44.PubMedCrossRef
52.
Chen MS, Huber AB, van der Haar ME, et al. Nogo-A is a myelin-associated neurite outgrowth inhibitor and an antigen for monoclonal antibody IN-1. Nature. 2000;403(6768):434–9.PubMedCrossRef
53.
Schwab ME, Strittmatter SM. Nogo limits neural plasticity and recovery from injury. Curr Opin Neurobiol. 2014;27:53–60.PubMedCrossRef
54.
Huber AB, Weinmann O, Brosamle C, et al. Patterns of Nogo mRNA and protein expression in the developing and adult rat and after CNS lesions. J Neurosci. 2002;22(9):3553–67.PubMed
55.
Dodd DA, Niederoest B, Bloechlinger S, et al. Nogo-A, -B, and -C are found on the cell surface and interact together in many different cell types. J Biol Chem. 2005;280(13):12494–502.PubMedCrossRef
56.
Wang KC, Koprivica V, Kim JA, et al. Oligodendrocyte-myelin glycoprotein is a Nogo receptor ligand that inhibits neurite outgrowth. Nature. 2002;417(6892):941–4.PubMedCrossRef
57.
Nash M, Pribiag H, Fournier AE, Jacobson C. Central nervous system regeneration inhibitors and their intracellular substrates. Mol Neurobiol. 2009;40(3):224–35.PubMedCrossRef
58.
Kempf A, Tews B, Arzt ME, et al. The sphingolipid receptor S1PR2 is a receptor for Nogo-a repressing synaptic plasticity. PLoS Biol. 2014;12(1):e1001763.PubMedPubMedCentralCrossRef
59.
Montani L, Gerrits B, Gehrig P, et al. Neuronal Nogo-A modulates growth cone motility via Rho-GTP/LIMK1/cofilin in the unlesioned adult nervous system. J Biol Chem. 2009;284(16):10793–807.PubMedPubMedCentralCrossRef
60.
Gou X, Zhang Q, Xu N, et al. Spatio-temporal expression of paired immunoglobulin-like receptor-B in the adult mouse brain after focal cerebral ischaemia. Brain Inj. 2013;27(11):1311–5.PubMedCrossRef
61.
Mi S, Pepinsky RB, Cadavid D. Blocking LINGO-1 as a therapy to promote CNS repair: from concept to the clinic. CNS Drugs. 2013;27(7):493–503.PubMedCrossRef
62.
Barrette B, Vallieres N, Dube M, Lacroix S. Expression profile of receptors for myelin-associated inhibitors of axonal regeneration in the intact and injured mouse central nervous system. Mol Cell Neurosci. 2007;34(4):519–38.PubMedCrossRef
63.
Fujita Y, Yamashita T. Axon growth inhibition by RhoA/ROCK in the central nervous system. Frontiers Neurosci. 2014;8:338.CrossRef
64.
Teng FY, Tang BL. Why do Nogo/Nogo-66 receptor gene knockouts result in inferior regeneration compared to treatment with neutralizing agents? J Neurochem. 2005;94(4):865–74.PubMedCrossRef
65.
Lee JK, Geoffroy CG, Chan AF, et al. Assessing spinal axon regeneration and sprouting in Nogo-, MAG-, and OMgp-deficient mice. Neuron. 2010;66(5):663–70.PubMedPubMedCentralCrossRef
66.
Schmandke A, Schmandke A, Schwab ME. Nogo-A: multiple roles in CNS development, maintenance, and disease. Neuroscientist. 2014;20(4):372–86.PubMedCrossRef
67.
Chong SY, Rosenberg SS, Fancy SP, et al. Neurite outgrowth inhibitor Nogo-A establishes spatial segregation and extent of oligodendrocyte myelination. Proc Natl Acad Sci USA. 2012;109(4):1299–304.PubMedCrossRef
68.
Gonzenbach RR, Zoerner B, Schnell L, et al. Delayed anti-nogo-a antibody application after spinal cord injury shows progressive loss of responsiveness. J Neurotrauma. 2012;29(3):567–78.PubMedCrossRef
69.
70.
Tsai SY, Papadopoulos CM, Schwab ME, Kartje GL. Delayed anti-nogo-a therapy improves function after chronic stroke in adult rats. Stroke. 2011;42(1):186–90.PubMedCrossRef
71.
Markus TM, Tsai SY, Bollnow MR, et al. Recovery and brain reorganization after stroke in adult and aged rats. Ann Neurol. 2005;58(6):950–3.PubMedCrossRef
72.
Wahl AS, Omlor W, Rubio JC, et al. Neuronal repair. Asynchronous therapy restores motor control by rewiring of the rat corticospinal tract after stroke. Science (New York, NY). 2014;344(6189):1250–5.CrossRef
73.
Freund P, Schmidlin E, Wannier T, et al. Nogo-A-specific antibody treatment enhances sprouting and functional recovery after cervical lesion in adult primates. Nat Med. 2006;12(7):790–2.PubMedCrossRef
74.
Zagrebelsky M, Schweigreiter R, Bandtlow CE, et al. Nogo-A stabilizes the architecture of hippocampal neurons. J Neurosci. 2010;30(40):13220–34.PubMedCrossRef
75.
Delekate A, Zagrebelsky M, Kramer S, et al. NogoA restricts synaptic plasticity in the adult hippocampus on a fast time scale. Proc Natl Acad Sci. 2011;108(6):2569–74.PubMedPubMedCentralCrossRef
76.
77.
Zemmar A, Weinmann O, Kellner Y, et al. Neutralization of Nogo-A enhances synaptic plasticity in the rodent motor cortex and improves motor learning in vivo. J Neurosci. 2014;34(26):8685–98.PubMedPubMedCentralCrossRef
78.
Wills ZP, Mandel-Brehm C, Mardinly AR, et al. The nogo receptor family restricts synapse number in the developing hippocampus. Neuron. 2012;73(3):466–81.PubMedPubMedCentralCrossRef
79.
Lee JY, Petratos S. Multiple sclerosis: does Nogo play a role? Neuroscientist. 2013;19(4):394–408.PubMedCrossRef
80.
Karnezis T, Mandemakers W, McQualter JL, et al. The neurite outgrowth inhibitor Nogo A is involved in autoimmune-mediated demyelination. Nat Neurosci. 2004;7(7):736–44.PubMedCrossRef
81.
Fontoura P, Ho PP, DeVoss J, et al. Immunity to the extracellular domain of Nogo-A modulates experimental autoimmune encephalomyelitis. J Immunol. 2004;173(11):6981–92.PubMedCrossRef
82.
Fontoura P, Steinman L. Nogo in multiple sclerosis: growing roles of a growth inhibitor. Journal of the neurological sciences. J Neurol Sci. 2006;245(1–2):201–10.PubMedCrossRef
83.
Petratos S, Ozturk E, Azari MF, et al. Limiting multiple sclerosis related axonopathy by blocking Nogo receptor and CRMP-2 phosphorylation. Brain. 2012;135(Pt 6):1794–818.PubMedPubMedCentralCrossRef
84.
85.
Nikic I, Merkler D, Sorbara C, et al. A reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis. Nat Med. 2011;17(4):495–9.PubMedCrossRef
86.
Tomassini V, d’Ambrosio A, Petsas N, et al. The effect of inflammation and its reduction on brain plasticity in multiple sclerosis: MRI evidence. Hum Brain Mapp. 2016;37(7):2431–45.PubMedPubMedCentralCrossRef
87.
Bareyre FM, Kerschensteiner M, Raineteau O, et al. The injured spinal cord spontaneously forms a new intraspinal circuit in adult rats. Nat Neurosci. 2004;7(3):269–77.PubMedCrossRef
88.
Kerschensteiner M, Bareyre FM, Buddeberg BS, et al. Remodeling of axonal connections contributes to recovery in an animal model of multiple sclerosis. J Exp Med. 2004;200(8):1027–38.PubMedPubMedCentralCrossRef
89.
Theotokis P, Lourbopoulos A, Touloumi O, et al. Time course and spatial profile of Nogo-A expression in experimental autoimmune encephalomyelitis in C57BL/6 mice. J Neuropathol Exp Neurol. 2012;71(10):907–20.PubMedCrossRef
90.
Anderson JM, Hampton DW, Patani R, et al. Abnormally phosphorylated tau is associated with neuronal and axonal loss in experimental autoimmune encephalomyelitis and multiple sclerosis. Brain. 2008;131(Pt 7):1736–48.PubMedCrossRef
91.
Denic A, Johnson AJ, Bieber AJ, et al. The relevance of animal models in multiple sclerosis research. Pathophysiology. 2011;18(1):21–9.PubMedCrossRef
92.
Jaillard C, Harrison S, Stankoff B, et al. Edg8/S1P5: an oligodendroglial receptor with dual function on process retraction and cell survival. J Neurosci. 2005;25(6):1459–69.PubMedCrossRef
93.
Pernet V, Joly S, Christ F, et al. Nogo-A and myelin-associated glycoprotein differently regulate oligodendrocyte maturation and myelin formation. J Neurosci. 2008;28(29):7435–44.PubMedCrossRef
94.
Syed YA, Baer AS, Lubec G, et al. Inhibition of oligodendrocyte precursor cell differentiation by myelin-associated proteins. Neurosurg Focus. 2008;24(3–4):E5.PubMedCrossRef
95.
Mi S, Miller RH, Lee X, et al. LINGO-1 negatively regulates myelination by oligodendrocytes. Nat Neurosci. 2005;8(6):745–51.PubMedCrossRef
96.
Mi S, Hu B, Hahm K, et al. LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis. Nat Med. 2007;13(10):1228–33.PubMedCrossRef
97.
Mi S, Miller RH, Tang W, et al. Promotion of central nervous system remyelination by induced differentiation of oligodendrocyte precursor cells. Ann Neurol. 2009;65(3):304–15.PubMedCrossRef
98.
Lee X, Yang Z, Shao Z, et al. NGF regulates the expression of axonal LINGO-1 to inhibit oligodendrocyte differentiation and myelination. J Neurosci. 2007;27(1):220–5.PubMedCrossRef
99.
Wootla B, Watzlawik JO, Warrington AE, et al. Naturally occurring monoclonal antibodies and their therapeutic potential for neurologic diseases. JAMA Neurol. 2015;72(11):1346–53.PubMedCrossRef
100.
Satoh J, Onoue H, Arima K, Yamamura T. Nogo-A and nogo receptor expression in demyelinating lesions of multiple sclerosis. J Neuropathol Exp Neurol. 2005;64(2):129–38.PubMedCrossRef
101.
Reindl M, Khantane S, Ehling R, et al. Serum and cerebrospinal fluid antibodies to Nogo-A in patients with multiple sclerosis and acute neurological disorders. J Neuroimmunol. 2003;145(1–2):139–47.PubMedCrossRef
102.
Meininger V, Pradat PF, Corse A, et al. Safety, pharmacokinetic, and functional effects of the nogo-a monoclonal antibody in amyotrophic lateral sclerosis: a randomized, first-in-human clinical trial. PLoS One. 2014;9(5):e97803.PubMedPubMedCentralCrossRef
103.
Tran JQ, Rana J, Barkhof F, et al. Randomized phase I trials of the safety/tolerability of anti-LINGO-1 monoclonal antibody BIIB033. Neurol Neuroimmunol Neuroinflamm. 2014;1(2):e18.PubMedPubMedCentralCrossRef
104.
Cadavid D, Balcer L, Galetta S, et al. Evidence of remyelination with the anti-LINGO-1 monoclonal antibody BIIB033 after acute optic neuritis. Neurology. 2015; E46.
105.
Noseworthy JH, Vandervoort MK, Wong CJ, Ebers GC. Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial: the Canadian Cooperation MS Study Group. Neurology. 1990;40(6):971–5.PubMedCrossRef
106.
di Nuzzo L, Orlando R, Nasca C, Nicoletti F. Molecular pharmacodynamics of new oral drugs used in the treatment of multiple sclerosis. Drug Design Develop Ther. 2014;8:555–68.
107.
Bonnan M, Ferrari S, Bertandeau E, et al. Intrathecal rituximab therapy in multiple sclerosis: review of evidence supporting the need for future trials. Curr Drug Targets. 2014;15(13):1205–14.PubMedCrossRef
108.
Bien-Ly N, Boswell CA, Jeet S, et al. Lack of widespread BBB disruption in Alzheimer’s disease models: focus on therapeutic antibodies. Neuron. 2015;88(2):289–97.PubMedCrossRef
109.
Pepinsky RB, Shao Z, Ji B, et al. Exposure levels of anti-LINGO-1 Li81 antibody in the central nervous system and dose-efficacy relationships in rat spinal cord remyelination models after systemic administration. J Pharmacol Exp Ther. 2011;339(2):519–29.PubMedCrossRef
110.
Petereit HF, Rubbert-Roth A. Rituximab levels in cerebrospinal fluid of patients with neurological autoimmune disorders. Mult Scler. 2009;15(2):189–92.PubMedCrossRef
111.
Tran J, Palaparthy R, Zhao J, et al. Safety, tolerability and pharmacokinetics of the anti-LINGO-1 monoclonal antibody BIIB033 in healthy volunteers and subjects with multiple sclerosis. Neurology. 2012;78((Meeting Abstracts 1)):P02.021.
112.
Greenberg BM, Rodriguez M, Kantarci O, et al. Safety and tolerability of the remyelinating therapeutic antibody rHIgM22 in patients with stable multiple sclerosis. Neurology. 2015:E48–E49.
113.
Willi R, Schwab ME. Nogo and Nogo receptor: relevance to schizophrenia? Neurobiol Dis. 2013;54:150–7.PubMedCrossRef
114.
Lewis CM, Levinson DF, Wise LH, et al. Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: schizophrenia. Am J Hum Genet. 2003;73(1):34–48.PubMedPubMedCentralCrossRef
115.
Willi R, Weinmann O, Winter C, et al. Constitutive genetic deletion of the growth regulator Nogo-A induces schizophrenia-related endophenotypes. J Neurosci. 2010;30(2):556–67.PubMedCrossRef
116.
Budel S, Padukkavidana T, Liu BP, et al. Genetic variants of Nogo-66 receptor with possible association to schizophrenia block myelin inhibition of axon growth. J Neurosci. 2008;28(49):13161–72.PubMedPubMedCentralCrossRef
117.
Craveiro LM, Weinmann O, Roschitzki B, et al. Infusion of anti-Nogo-A antibodies in adult rats increases growth and synapse related proteins in the absence of behavioral alterations. Exp Neurol. 2013;250:52–68.PubMedCrossRef
118.
Oertle T, van der Haar ME, Bandtlow CE, et al. Nogo-A inhibits neurite outgrowth and cell spreading with three discrete regions. J Neurosci. 2003;23(13):5393–406.PubMed
119.
Schnell L, Schwab ME. Axonal regeneration in the rat spinal cord produced by an antibody against myelin-associated neurite growth inhibitors. Nature. 1990;343(6255):269–72.PubMedCrossRef
Metadaten
Titel
Nogo-A Antibodies for Progressive Multiple Sclerosis
verfasst von
Benjamin V. Ineichen
Patricia S. Plattner
Nicolas Good
Roland Martin
Michael Linnebank
Martin E. Schwab
Publikationsdatum
01.03.2017
Verlag
Springer International Publishing
Erschienen in
CNS Drugs / Ausgabe 3/2017
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI
https://doi.org/10.1007/s40263-017-0407-2

Weitere Artikel der Ausgabe 3/2017

CNS Drugs 3/2017 Zur Ausgabe

Current Opinion

Binge Drinking: Current Diagnostic and Therapeutic Issues

Review Article

Outcome Measures in Clinical Trials for Multiple Sclerosis

Editorial

Clozapine for Treatment-Resistant Schizophrenia: Still the Gold Standard?

Original Research Article

Impact of Drug Manipulation on Seizure Freedom in Adults with Uncontrolled Epilepsy: A Prospective Controlled Study in Rural China

Systematic Review

Cardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and Atomoxetine

Original Research Article

Benzodiazepine Use and Risk of Developing Alzheimer’s Disease: A Case-Control Study Based on Swiss Claims Data

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise